<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
<title>中国证监会行政处罚决定书（蝶彩资产管理（上海）有限公司、谢风华、阙文斌）</title>
<style>
.topLine{
	height:6px;
	overflow:hidden;
	border-top:4px solid #F32F30;
	border-bottom:1px solid #F32F30;
}
.docTitle{
	font-weight:bold;
	font-size:18px;
	color:#F32F30;
	white-space:nowrap;
	text-align:center;
	margin:20px 0px 30px;
}
</style>
<style id="MyStyle">
.content P,.content Table , .content TD,.content SPAN{
	TEXT-DECORATION: none;
	word-break:break-all !important;
	word-wrap:break-word !important;
	font-family:楷体
}
.content Table{
	table-layout:auto;
}
.separator{
	color:#F32F30;
	BORDER-BOTTOM-STYLE: dotted; BORDER-LEFT-STYLE: dotted; BORDER-RIGHT-STYLE: dotted; BORDER-TOP-STYLE: dotted;
	font-weight:none;
	display:none;
}
.appendix{
	display:none;
}
.contentss{
	overflow-x:auto;width:920px;padding-bottom:30px
}
</style>
<link href="../../css/detail.css" rel="stylesheet" media="screen" type="text/css">
<link href="../../css/print.css" rel="stylesheet" media="print" type="text/css">
<style media="print">
.contentss{
	overflow-x:auto;width:650px;padding-bottom:30px
}
</style>
</head>

<body>
<div class="container" id="gkml" style="margin:0px auto;">
    <div class="header"><IMG SRC="../../images/logo.jpg" width="984"></div>
    <div class="main">
        <!--div class="rowOfCurrentPosition">
            当前位置：文体综合类 &gt; 通知公告公示123
        </div-->
		<div class="headInfo" style="position:relative;">
		<table border=0 cellspacing=0 cellpadding=0 style="width:90%;" id="headContainer">
		<tbody>
			<tr>
				<td colspan="2">
					<table border=0 cellspacing=0 cellpadding=0>
						<tr>
							<td width="50%"><B>索 引 号:</B>40000895X/</td>
							<td>
								<B>分类:</B>
								<span id="lSubcat">行政处罚&nbsp;;&nbsp;行政处罚决定</span>
							</td>
						</tr>
					</table>				
				</td>
			</tr>
			<tr>
				<td colspan="2">
					<table border=0 cellspacing=0 cellpadding=0>
						<tr>
							<td width="50%">
								<B>发布机构:</B> 
								<span>证监会</span>							
							</td>
							<td>
								<B>发文日期:</B>
								<span>2017年08月10日</span>								
							</td>
						</tr>
					</table>				
				</td>
			</tr>
			<tr>
				<td colspan="2">
					<B>名　　称:</B> 
					<span id="lTitle">中国证监会行政处罚决定书（蝶彩资产管理（上海）有限公司、谢风华、阙文斌）</span>
		            
				</td>
			</tr>
			<tr>
				<td colspan="2">
					<table border=0 cellspacing=0 cellpadding=0>
						<tr>
							<td width="50%">
								<B>文　　号:</B> 
								<span>〔2017〕80号</span>					           
							</td>
							<td>
								<B>主 题 词:</B> 
								<span></span>								
							</td>
						</tr>
					</table>				
				</td>
			</tr>
			<!--<tr>
				<td colspan="2">
				<b>内容提要:</b>
				</td>
			</tr>
			<tr>
				<td colspan="2">
					<span></span>					
				</td>
			</tr>-->
		</tbody>
		</table>
		</div>        
	<OBJECT   id="WebBrowser"   classid="CLSID:8856F961-340A-11D0-A96B-00C04FD705A2"   height="0"   width="0"></OBJECT> 	
        <div class="mainContainer" >
			<div STYLE=" width:800px">
				<p align="center"><br><font size="1" style="FONT-SIZE: 18pt; COLOR: red; FONT-FAMILY: 黑体"><strong>
				<script>
				var strssre="中国证监会行政处罚决定书（蝶彩资产管理（上海）有限公司、谢风华、阙文斌）";
				if(strssre.length>32)
				{
					if(strssre.length<50)
					{
						document.writeln(strssre.substring(0,25)+"<br/>");
						document.writeln(strssre.substring(25,strssre.length));
					}
					else if(strssre.length<67)
					{
						document.writeln(strssre.substring(0,25)+"<br/>");
						document.writeln(strssre.substring(25,49)+"<br/>");
						document.writeln(strssre.substring(49,strssre.length));
					}
					else
					{
						document.writeln(strssre.substring(0,25)+"<br/>");
						document.writeln(strssre.substring(25,49)+"<br/>");
						document.writeln(strssre.substring(49,70)+"<br/>");
						document.writeln(strssre.substring(70,strssre.length));
					}
				}
				else
				{
					document.writeln(strssre);
				}
				</script>
				</strong></font><br/><br/>
				<!--
				<font face="楷体_GB2312">〔2017〕80号</font><br>
				--></p>
			</div>

			
			<div class="contentss"  id="ContentRegion">				
				<div class="content"><P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; LINE-HEIGHT: 150%; TEXT-ALIGN: center"><SPAN style="FONT-SIZE: 10.5pt; COLOR: rgb(0,0,0); FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">〔2017〕80号</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: rgb(0,0,0); FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; LAYOUT-GRID-MODE: char; LINE-HEIGHT: 150%"><SPAN style="FONT-SIZE: 10.5pt; COLOR: rgb(0,0,0); FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p>&nbsp;</o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; LAYOUT-GRID-MODE: char; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">当事人：</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">蝶彩资产管理（上海）有限公司（以下简称蝶彩资产），</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">2012年5月成立，住所：</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">上海市浦东新区。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; LAYOUT-GRID-MODE: char; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">谢风华，男，1971年1月出生，蝶彩资产实际控制人，住址：上海市浦东新区。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; LAYOUT-GRID-MODE: char; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">阙文彬，男，1963年8月出生，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">恒康</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">医疗集团股份有限公司（以下简称恒康医疗；原甘肃独一味生物制药股份有限公司，以下简称独一味）控股股东及实际控制人，住址：</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">四川省成都市。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p16 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">依据《中华人民共和国证券法》（以下简称《证券法》）的有关规定，我会对</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">蝶彩资产、谢风华、阙文彬操纵“恒康医疗”股价一</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">案进行了立案调查、审理，并依法向当事人告知了作出行政处罚的事实、理由、依据及当事人依法享有的权利。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">应</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">当事人</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">的</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">要求，我会举行听证，听取了</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">其</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">陈述、申辩。本案现已调查、审理终结。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">经查明，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">当事人</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">存在以下违法事实：</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">一、蝶彩资产、谢风华和阙文彬</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">合谋操纵股价的筹划过程</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">2013年3月，阙文彬与谢风华在上海见面，阙文彬向谢风华表达了希望高价减持</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">“恒康医疗”</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">的意愿</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">谢风华表示可以通过</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">“</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">市值管理</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">”</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">的方式提高恒康医疗</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">“</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">价值</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">”</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">，进而</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">拉升</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">股价，实现阙文彬高价减持</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">“恒康医疗”</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">的目的</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">2013年5月7日，德邦证券</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">有限责任公司（以下简称德邦证券）</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">、兴业银行</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">股份有限公司（</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">以下简称兴业银行）</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">和阙文彬三方签署《德邦证券</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">－</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">兴业银行定向资产管理业务资产管理合同》</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">（以下简称《资产管理合同》）</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">，阙文彬为委托人，德邦证券为管理人，兴业银行为托管</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">人。根据合同约定，自管理人确认委托资产全部到账后，向委托人和托管人发送</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">《委托资产起始运作通知书》</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">，委托人和托管人双方确认签收的当日（若非同日签收，以最后一方签收日的当日）合同开始生效。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">2013年5月</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">8日，阙文彬将2000万股</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">“恒康医疗”</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">托管转至资产管理账户。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">根据合同约定的生效条件，《资产管理合同》于</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">2013年5月</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">9日</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">生效。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">德邦证券、蝶彩资产和阙文彬三方签署《研究顾问协议》，协议约定蝶彩资产作为研究顾问</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">机构</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">提供顾问服务</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">顾问服务期限与定向计划的委托管理期限相同。蝶彩资产根据阙文彬</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">在</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">“恒康医疗”股价</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">不低于</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">20元/股</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">的情况下对持有的2,000万股</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">“恒康医疗”</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">进行减持</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">的需求，提供减持策略报告和操作方案</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">，蝶彩资产收取</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">研究顾问费，研究顾问费按减持成交金额的</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">12.5%计提，收取金额为计提金额</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">扣除管理费、托管费和交易费用后</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">的余额</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; BACKGROUND: rgb(255,255,0); FONT-FAMILY: '宋体'; mso-spacerun: 'yes'; mso-highlight: rgb(255,255,0)"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">二、</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">蝶彩资产、谢风华和阙文彬</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">合谋操纵股价的实施过程</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">从2013年5月9日（即按照</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">《研究顾问协议》</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">和《资产管理合同》的相关约定确定</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">蝶彩资产开始履行顾问服务义务的时间）起至7月4日阙文彬完成减持“恒康医疗”的期间（以下简称操纵期间），</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">蝶彩资产及谢风华</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">向阙文彬提出一系列“市值管理”建议，阙文彬通过实施部分“市值管理”建议，操纵“恒康医疗”股价</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">具体如下：</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">一是</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">蝶彩资产、谢风华和阙文彬实施合谋操纵股价的主观意图。《研究顾问协议》的签订确立了谢风华、蝶彩资产与阙文彬在不低于20元/股减持股票事项上的合作关系；协议中约定蝶彩资产</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">研究顾问费按减持成交金额的</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">12.5%计提，绑定了双方的共同利益，蝶彩资产、谢风华和阙文彬存在利用“市值管理”拉抬“恒康医疗”股价并减持获利的共同动机；同时，谢风华在询问笔录中承认希望恒康医疗能够落实“市值管理”建议，相互配合共同实现“市值管理”目标，说明谢风华存在实现上述“市值管理”目标的主观意愿。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">二是</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">蝶彩资产、谢风华和阙文彬实施合谋操纵股价的客观行为。蝶彩资产的工作人员及谢风华通过邮件发送给阙文彬的《市值管理备忘录》和恒康医疗在涉案期间的一系列行为明确了谢风华、蝶彩资产实际参与了“市值管理”事项，并发挥了重要作用。经查，蝶彩资产的工作人员、谢风华在发送给阙文彬的《市值管理备忘录》中提出的“市值管理”建议包括：建议恒康医疗加快战略转型；建议采取收购医院、安排行业研究员调研、安排财经公关和证券媒体采访等方式改善恒康医疗资本市场形象；建议恒康医疗“加强”信息披露，将恒康医疗正在做的对股价有提升的项目向市场披露来进行“市值管理”。从恒康医疗在涉案期间披露</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">收购三家医院、“DYW101”和“独一味牙膏”</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">等事项可以看出，阙文彬采纳了谢风华、蝶彩资产提出的“市值管理”建议，并按照恒康医疗实际情况和已有的可供利用事项实施了“市值管理”行为。其中，恒康医疗未完整披露收购医院价款，对</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">《补充协议》</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">及3,000万元补偿款未予披露；</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">未及时披露“DYW101”项目，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">并用误导性陈述影响</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">投资者预期</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">；</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">在操纵期间选择时点披露</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">“</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">独一味牙膏</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">”</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">研发及生产进展，增加操纵期间“利好”信息披露密度，影响投资者预期</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">三是蝶彩资产、谢风华和阙文彬合谋操纵股价目标的完成。2013年7月3日、4日阙文彬成功以20元/股均价减持“恒康医疗”2200万股（其中2000万股为“资产管理计划”所涉恒康医疗股票），蝶彩资产、谢风华完成了与阙文彬约定的“市值管理”目标。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">三、</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">蝶彩资产、谢风华和阙文彬</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">合谋操纵股价</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">的</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">结</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">果</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">2013年5月</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">9</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">日至7月3日期间，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">“恒康医疗”股价</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">累计上涨</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">24</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">.</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">86</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">%</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">（以前一个交易日</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">的收盘价为基数，下同</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">）</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">，同期中小板综指累计下跌</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">1</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">.</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">24</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">%，偏离</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">26</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">.</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">10</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">个百分点；同期</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">深证</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">医药行业指数累计下跌</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">1.91</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">%，偏离</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">26.77</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">个百分点</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">2013年5月</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">9</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">日至7月4日期间，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">“恒康医疗”股价</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">累计上涨</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">15.52</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">%，同期中小板综指累计下跌0.</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">80</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">%，偏离</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">16.32</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">个百分点；同期</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">深证</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">医药行业指数累计下跌</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">3.11</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">%，偏离</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">18.63</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">个百分点。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">2013年7月5日至8月30日</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">期间，阙文彬</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">减持</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">“恒康医疗”</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">完成后，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">股价</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">累计下跌</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">2.45</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">%，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">同期</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">中小板综指</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">累计上涨</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">6.94%、深证医药</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">行业</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">指数</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">累计上涨</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">3.03%</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">恒康医疗没有发布任何对股价有影响的信息，其股价因缺乏利好信息支撑而下滑，涨势显著弱于可比指数。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; COLOR: rgb(0,0,255); FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">2013年7月3日</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">、</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">4日，阙文彬通过大宗交易系统减持</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">“</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">恒康医疗</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">”</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">2200万股，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">共获利</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">51,621,068元</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">其中包括“德邦证券</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">－</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">兴业银行定向资产管理业务资产管理合同”约定的2000万股，7月3日</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">、</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">4日各减持1000万股，减持均价20元/股；7月4日阙文彬自主减持200万股，减持均价19.91元/股。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">2013年7月5日，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">阙文彬按照约定支付了蝶彩资产研究顾问费</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">48,580,000元</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">以上事实，有</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">相关人员邮件、询问笔录、相关协议、项目资料、</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">深圳证券交易所出具的盈利计算表</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">等证据证明，足以认定。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; BACKGROUND: rgb(255,255,0); FONT-FAMILY: '宋体'; mso-spacerun: 'yes'; mso-highlight: rgb(255,255,0)"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">阙文彬与蝶彩资产、谢风华合谋，利用作为上市公司</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">控股股东及实际控制人具有的</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">信息优势</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">，控制恒康医疗密集发布利好信息，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">人为操纵信息披露的内容</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">和</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">时点，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">未及时、真实</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">、准确</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">、</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">完整披露对恒康医疗不利的信息，夸大恒康医疗研发能力，选择时点披露恒康医疗已有的重大利好</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">信息，借“市值管理”名义，行操纵股价之实</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">。通过</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">上述一系列信息披露的综合起效，客观上误导了投资者，影响了“恒康医疗”股价，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">实现</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">了</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">阙文彬高价减持</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">“恒康医疗”</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">的目的</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">，违反了《证券法》第七十七条第一款的规定，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">构成</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">第二百零三条所述操纵证券市场行为。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">蝶彩资产、谢风华与阙文彬合谋操纵股价违法所得51,621,068元。其中，蝶彩资产、谢风华</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">负责策划恒康医疗“市值管理”方案</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">蝶彩资产起主导作用，非法获取</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">48,580,000元，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">应承担主要责任，谢风华</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">是直接负责的主管人员；</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">阙文彬起配合作用，非法获取</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">3,041,068</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">元</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">应承担次要责任。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">当事人蝶彩资产、谢风华及其代理人在听证中提出：第一，当事人不具有控制恒康医疗信息披露以实施操纵“恒康医疗”股价的主观故意。在《独一味战略发展规划》中，蝶彩资产提出了对独一味五年分别要实现的市值管理目标。其以持续提升恒康医疗内在价值为目的的“市值管理”服务符合国家相关规定。《研究顾问协议》中对顾问服务费用的约定属于正常的市场行为，本质上带有风险管理的性质，不能因此倒推其具有操纵股价的动机。第二，蝶彩资产、谢风华没有控制恒康医疗三项信息披露从而实施合谋操纵股价的具体行为。从信息披露程序可看出，恒康医疗信息披露无须征求蝶彩资产、谢风华意见；该信息披露事项与蝶彩资产、谢风华向阙文彬提出的“市值管理”建议无关。第三，关于蝶彩资产实施减持操作的事实认定错误，在案无任何证据证明蝶彩资产发出了减持指令，蝶彩资产仅仅向阙文彬提供了减持建议和三家可供选择的接盘机构，没有为阙文彬安排过接盘方。第四，“恒康医疗”股价的变化分析不能推出当事人合谋操纵股价，反而证明了恒康医疗实施“市值管理”对公司价值的正面影响；此外，《行政处罚事先告知书》中对公告减持后的股价涨幅计算存在误差。第五，蝶彩资产提供的“市值管理”服务合法合规，与以“市值管理”为名行操纵股价之实的行为具有根本的区别。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">蝶彩资产、谢风华在听证会后补充提供申辩材料：第一，在《听证申辩补充证据说明材料》中提出，蝶彩资产和谢风华关于价值创造的实践符合国际咨询公司的业务模式，不存在短期操纵股价获利的交易动机和行为。第二，在《听证申辩补充证据说明材料（二）》中提出，恒康医疗根据自身经营计划决定实施并公告的三个项目均与蝶彩资产的咨询建议内容无关，双方合作期间蝶彩资产提出的咨询建议基本上未得到阙文彬的反馈和采纳，因此蝶彩资产不存在</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">与</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">阙文彬合谋操纵“恒康医疗”股价的事实。第三，其提交的《专家意见书》中，专家一致认为蝶彩资产和谢风华的行为属于上市公司市值管理中正常的咨询服务行为，在市值管理过程中提供正常的咨询服务，既不是减持交易的决策者或最终控制者，也不是恒康医疗信息披露的参与者；《行政处罚事先告知书》混淆了“合法的市值管理”和“利用市值管理操纵股价”的界限；即便正常的市值管理过程中，恒康医疗存在个别信息披露违规，蝶彩资产和谢风华不应对该行为承担责任，不宜认定为操纵股价。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">当事人阙文彬的代理人在听证中提出：第一，阙文彬没有操纵股价的主观意图。第二，阙文彬从未与谢风华、蝶彩资产实施合谋操纵股价的行为，从未配合、落实谢风华、蝶彩资产提出的不合理“市值管理”要求，从未控制上市公司发布公告，公告不存在任何虚假、误导。第三，公告发布后股价走势不存在异常状况，公司公告与公司在涉案期间股价大幅上涨的结果无关。第四，操纵期间及成本价认定错误，导致当事人的盈利金额计算错误。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">我会认为，第一，在主观方面，蝶彩资产、谢风华</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">、阙文彬具</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">有操纵“恒康医疗”股价的故意。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">《研究顾问协议》的本质</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">可以</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">从协议由来、协议内容和相关各方具体行为三个角度判断。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">从协议的由来来看，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">结合</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">阙文彬、谢风华等多份询问笔录，该份协议签订的背景是阙文彬由于研发肿瘤药物而意图以</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">20元/股</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">的价格减持</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">“恒康医疗”</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">筹集资金</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">；</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">从协议的内容来看，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">其核心内容</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">是阙文彬以不低于</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">20元/股</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">的价格减持2000万股</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">“恒康医疗”</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">，而</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">不是</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">通过“市值管理”提升</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">恒康医疗的</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">“价值”</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">；</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">从相关各方的具体行为来看，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">蝶彩资产在《市值管理备忘录》中多次强调恒康医疗</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">须</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">采纳并落实“市值管理”建议才能</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">拉升</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">“恒康医疗”</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">股价。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">蝶彩资产诸如加快收购医院、加强信息披露、安排行业研究员调研等“市值管理”建议，均是</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">为了</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">直接或间接影响</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">“恒康医疗”股价</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">同时，恒康医疗和阙文彬利用已有可利用的事项</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">实施了蝶彩资产提出的多项“市值管理”建议，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">拉升“恒康医疗”股价</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">大幅</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">上扬</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">偏离可比指数。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">所以，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">《研究顾问协议》的本质即是提升</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">“恒康医疗”股</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">价</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">，而非系统全面地提升恒康医疗价值，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">蝶彩资产、谢风华</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">、阙文彬</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">以“市值管理”为名而行操纵市场之实。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">此外，蝶彩资产提供的申辩证据中有</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">4</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">份《独一味市值管理工作备忘录》，其中仅第二份明确提到了独一味五年的战略发展规划，其表述为“蝶彩资产于</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">2013年5月22日针对独一味（以下简称贵司）市值管理要求审阅了贵司拟定的战略发展规划，战略发展规划明确了公司未来五年发展路径、利润目标和市值目标。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">”由此可见，五年发展规划并非蝶彩资产拟定，而是恒康医疗已经制定完成，仅由蝶彩资产审阅，该申辩证据无法证明蝶彩资产致力于帮助恒康医疗提升内在价值以谋求长期发展的主张。《研究顾问协议》中并无五年的战略发展规划的表述和顾问服务建议，并且蝶彩资产与阙文彬的合作，在阙文彬减持股票完成后即结束，蝶彩资产、谢风华也没有为恒康医疗提供长期市值管理的客观行为。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">综上，我会对该项</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">申辩意见不予采纳。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">第二，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">蝶彩资产、谢风华通过邮件发送给阙文彬的《市值管理备忘录》、恒康医疗在涉案期间的一系列行为明确了蝶彩资产、谢风华、阙文彬实际参与了“市值管理”事项，利用“市值管理”实现以不低于</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">20元/股减持“恒康医疗”的目标。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">“</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">市值管理</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">”</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">建议包括：</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">建议</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">恒康医疗加快战略转型</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">；建议</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">采取收购医院</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">、</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">安排行业研究员调研、安排财经公关和证券媒体采访</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">等方式</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">改善恒康医疗资本市场形象</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">；</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">建议</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">恒康医疗</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">“加强”信息披露</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">等。恒康医疗确实按照蝶彩资产提出的“市值管理”思路，通过</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">不及时、真实、准确、完整披露公司</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">重大信息等一系列方式</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">进行</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">了“</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">市值管理</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">”，实现“恒康医疗”股价上扬的目标</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">其中，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">“加强”信息披露</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">方面</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">具体情况如下：</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">1.</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">&nbsp;</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">未完整、准确披露收购三家医院对价情况</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">2013年6月</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">恒康医疗</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">发布</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">收购蓬溪医院、资阳医院和德阳医院</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">三家医院的公告。经调查，收购</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">过程中除签订收购合同外，恒康医疗董事会秘书郭</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">某曾通过</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">电子邮件</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">发送给阙文彬</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">《补偿协议》，协议显示恒康医疗关联方需向刘</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">某</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">均</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">（</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">收购</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">项目介绍人）</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">支付3,000万元补偿款</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">，但</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">恒康医疗未披露《补偿协议》及补偿款的支付条件和金额</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">等情况，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">表面上降低了收购成本，增强了投资者对收购事项收益的预期，对“恒康医疗”股价产生积极影响。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">2.</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">&nbsp;</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">未真实、准确披露</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">“DYW101”项目研发情况</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">2013年6月恒康医疗</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">公告称其</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">全资子公司上海独一味生物科技有限公司（</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">以下</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">简称上海独一味）</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">和</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">美国Apexigen公司等协作研发</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">完成了</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">“</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">DYW101</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">”</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">项目第一阶段研究。经查，“DYW101”项目实际由四川恒康发展有限责任公司子公司上海津曼特生物科技有限公司进行</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">上海独一味不具备产品研发的条件和能力，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">其</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">仅为名义参与方</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">。该</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">公告</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">夸大</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">了上海独一味的研发能力，误导投资者，有利于提升“恒康医疗”股价。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">3.</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">&nbsp;</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">未及时披露独一味牙膏研发进展情况</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">2013年6月24日恒康医疗发布公告</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">称</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">独一味牙膏于日前研制完毕。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">经查，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">该</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">研发工作2011年之前就已完成</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">；</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">2011年2月恒康医疗获得</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">相关</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">注册商标</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">；</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">2011年6月</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">初</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">恒康医疗提出</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">相关</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">发明专利申请</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">该</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">公告发布时间与实际研发时间差异较大，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">选择时点披露</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">相关</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">研发进展，增加</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">重大</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">利好信息披露密度，影响投资者</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">收益</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">预期</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">，从而提升“恒康医疗”股价。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">此外，恒康医疗落实蝶彩资产提出的“市值管理”建议，必须结合恒康医疗的实际情况，从恒康医疗的实际出发，把蝶彩资产提出的“市值管理”建议内化为切实可行的具体方案。从恒康医疗披露一系列与蝶彩资产“市值管理”建议相符合的信息来看，蝶彩资产的“市值管理”建议被阙文彬充分认可、吸收并实际采纳。最终导致“恒康医疗”股价异常上涨，阙文彬支付、蝶彩资产非法获得</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">48,580,000元</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">的高额咨询服务费。因此，《听证申辩补充证据说明材料（二）》中提出的恒康医疗公告的三个项目均与蝶彩资产的咨询建议内容无关、蝶彩资产的咨询建议没有被阙文彬和恒康医疗采纳的申辩意见不成立。综上，我会对该项</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">申辩意见不予采纳。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">第三，《</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">研究顾问</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">协议</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">》</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">明确约定</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">“以不低于</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">20元/股</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">的价格减持恒康医疗股票”</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">蝶彩资产为阙文彬提供“市值管理”建议的本质是把</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">“恒康医疗”股价拉升到</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">20元/股</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">的价</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">位</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">，与其在《听证申辩补充证据说明材料》中提出的国外公司咨询服务的内容有本质区别。因此，我会对</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">该项</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">申辩意见不予采纳。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">第四，关于专家一致认为蝶彩资产和谢风华在“市值管理”过程中提供的是正常咨询服务的问题。根据《</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">研究顾问</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">协议</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">》</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">明确约定</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">“以不低于</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">20元/股</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">的价格减持恒康医疗股票”</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">蝶彩资产为阙文彬提供“市值管理”建议的本质是把</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">“恒康医疗”股价拉升到</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">20元/股</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">的价</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">位</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">，属于典型的操纵“恒康医疗”股价的行为。蝶彩资产、谢风华以合法的形式掩盖非法的目的，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">借“市值管理”名义，行操纵股价之实</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">蝶彩资产、谢风华与阙文彬合谋操纵股价违法所得51,621,068元</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">其中，蝶彩资产、谢风华非法获取</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">48,580,000元</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">从当事人主观目的、客观行为、实际效果等完整的逻辑链条来看，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">蝶彩资产、谢风华与阙文彬合谋操纵“恒康医疗”股价的</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">事实清楚，证据确实充分，因此</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">《专家意见书》提出的结论意见不具有合理性。另外，《行政处罚事先告知书》并未涉及蝶彩资产、谢风华应当对恒康医疗的信息披露违规行为承担责任的事实。综上，我会对</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">该项</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">申辩意见不予采纳。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">第五，关于减持指令的具体下达和接盘方安排的事实认定问题。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">在认定蝶彩资产、谢风华和阙文彬合谋操纵</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">股价</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">的情况下，具体减持指令的下达</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">和接盘方的安排是否由蝶彩资产作出，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">并不影响合谋操纵</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">股价</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">的后果以及双方责任的</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">认定。我会对该申辩意见予以采纳，并对相关表述作出调整</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">第六，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">当事人提出减持后的股价涨幅计算存在误差，经核算，我会对该申辩意见予以采纳，并对减持后的股价涨幅作出调整。该项误差不影响当事人合谋操纵股价的结果，对当事人的认定和处理亦不产生影响。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">第七，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">2013年5月7日</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">德邦证券</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">、</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">兴业银行</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">和阙文彬签署</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">《资产管理合同》，约定该合同自管理人德邦证券确认委托资产全部到账、向委托人阙文彬和托管人兴业银行发送</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">《委托资产起始运作通知书》</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">并经双方确认签收后生效。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">同日，德邦证券、蝶彩资产和阙文彬签署《研究顾问协议》</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">，约定蝶彩资产提供顾问服务的期限同《资产管理合同》的委托管理期限。据此，当事人提出合同生效日期应为</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">2013年5月9日，作为操纵起点的股票价格应为合同生效前一日的收盘价，即2013年5月8日“恒康医疗”的收盘价。经查相关合同，我会</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">对此项申辩意见予以采纳。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">根据</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">当事人</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">违法行为的事实、性质、情节与社会危害程度，</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">依据《证券法》第</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">二百零三</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">条的规定，我会决定：</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">一、</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">没收蝶彩资产违法所得48,580,000元，并处以</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">97</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">,</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">160</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">,000元罚款；</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">二、</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">对谢风华给予警告，并处以</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">60万元罚款；</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">三、</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">没收阙文彬违法所得</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">3,041,068</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">元，并处</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">以</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">3,041,068</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">元罚款。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; TEXT-INDENT: 21pt; LINE-HEIGHT: 150%; TEXT-ALIGN: justify"><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">上述当事人应自收到本处罚决定书之日起15日内，将罚</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; COLOR: rgb(0,0,0); FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">没</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">款汇交中国证券监督管理委员会（开户银行：中信银行总行营业部，账号：7111010189800000162，由该行直接上缴国库），并将注有当事人名称的付款凭证复印件送中国证券监督管理委员会稽查局备案。当事人如果对本处罚决定不服，可在收到本处罚决定书之日起60日内向中国证券监督管理委员会申请行政复议，也可在收到本处罚决定书之日起6个月内直接向有管辖权的人民法院提起行政诉讼。复议和诉讼期间，上述决定不停止执行。</SPAN><SPAN style="FONT-WEIGHT: normal; FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; LINE-HEIGHT: 150%"><SPAN style="FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p>&nbsp;</o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; LINE-HEIGHT: 150%"><SPAN style="FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p>&nbsp;</o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; LINE-HEIGHT: 150%"><SPAN style="FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p>&nbsp;</o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; LAYOUT-GRID-MODE: char; LINE-HEIGHT: 150%"><SPAN style="FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p>　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　</o:p></SPAN><SPAN style="FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">中国证监会</SPAN><SPAN style="FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">　　&nbsp;</SPAN><SPAN style="FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">　</SPAN><SPAN style="FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">　　</SPAN><SPAN style="FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'"><o:p></o:p></SPAN></P>
<P class=p0 style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt"><SPAN style="FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　&nbsp; 2017年8月10日</SPAN><SPAN style="FONT-SIZE: 10.5pt; FONT-FAMILY: '宋体'; mso-spacerun: 'yes'">　</SPAN></P><!--EndFragment--></div></br>	
			</div>

			<div class="content">					
						
			</div>
			
			<div class="noprint" style="width:100%;overflow:hidden;border-bottom:1px solid gray;margin:8px 40px"></div>

			<div class="noprint" style="text-align:center;margin:8px 0px">
				<table style="font-size:12px">
				 <!--<td>
				  【字体：<a href="#" onclick="setSize('24px');" class="navy">大</a> <a href="#" onclick="setSize('16px');" class="navy">中</a> <a href="#" onclick="setSize('12px');" class="navy">小</a>】</td>
				<td align="right" width="10"></td>-->
				<td width="60">&nbsp;</td>
				<td width="80"><a href="#" onclick="document.all.WebBrowser.ExecWB(4,1)"><img src="/pub/images/save.gif" border=0></a></td>
				<td width="80"><a href="#" onclick="javascript:window.print()"><img src="/pub/images/openpage.gif" border=0></a></td>
				<td width="80"><a href="#" onclick="window.close()"><img src="/pub/images/close.gif" border=0></a></td>
				</tr>
				</table>
			</div>
		</div>
        <div class="bottomLine"></div>
    </div>
    <div class="footer">
        <div class="footerLine"></div>
        <div><a href="/pub/newsite/fzlm/gywm/" target=_blank>关于我们</a>&nbsp;-&nbsp;<a href="/pub/newsite/fzlm/flsm/" target=_blank>法律声明</a>&nbsp;-&nbsp;<a href="/pub/newsite/fzlm/lxwm/" target=_blank>联系我们</a></div>
<div>版权所有：中国证券监督管理委员会     京ICP备 05035542号</div>
          <div>地址：北京市西城区金融大街19号富凯大厦A座  邮编：100033</div>
        <div>建议使用IE5.5以上浏览器，分辨率1024*768</div>
    </div>
</div>
</body>
</html>
./t20170814_322133_ext.json